"If you're having trouble paying for your medications, Drug Company X may be able to help."
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.
The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).
Takeuchi et al has published their large experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy.
The diagnosis of axial spondyloarthritis (and anklylosing spondylitis) (axSpA) is often delayed and usually not diagnosed by rheumatologists; a recent metanalysis shows that longer delays were attributable to lower education levels, younger age at onset and absence of extra-articular manifestatio
A novel report from PNAS suggests that in osteoarthritis (OA), the damage is not entirely from body weight and mechanics, instead it may be from adipose tissue itself.
The fate of the Trump administration's "most favored nation" (MFN) rule for bringing down prescription drug prices remains uncertain as President-elect Joe Biden prepares to assume office later this month.